Resources

ELRIG has appointed Drs Hitesh Sanganee and Marcus Schindler to its Scientific Advisory Board (SAB).

Lonza and Engitix announced a licensing agreement to advance the development of antibody-drug conjugates (ADCs).

From first-in-class approvals to billion-dollar deals, Q2 2026 signals a new era for antibody innovation

eXmoor Pharma and Evox Therapeutics announce the successful completion of a technology transfer programme for Evox’s exosome-enabled gene editing technology.

Chris Molloy Q2 2026 finance report, investment in Draig Therapeutics, MHRA meeting, centure capital summit and upcoming BIA events

Theolytics has relocated to ARC Oxford, taking 5,500 SQF at the growing innovation campus.

UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion, including a record £2.05 billion in venture capital.

Solena Materials is a pioneering biotech company specialising in computationally-designed synthetic protein materials

Pioneer Group, a specialist life science infrastructure and venture building business, and Firoka, a hospitality and real estate group, have secured unanimous resolution to grant planning permission for the transformation of Ozone Leisure Park in Oxford.

The British Business Bank has invested in Draig Therapeutics as part of its $65 million Series B financing round.

The Milner Therapeutics Institute has joined the o2h Discovery Platinum Partner Programme, enabling eligible companies within its bio-incubator and wider affiliate network to access specialist drug discovery support through the o2h Kickstarter Award.

Milner Institute convenes science, industry, investors and charity funders for Pitch Day and Symposium

How to unlock the UK's innovative life sciences and biotech potential

Some of the UK's most promising student food innovators gathered at Colworth Science Park this month for the 2026 Ecotrophelia UK final, where seven university teams presented eco-innovative food concepts to a panel of industry judges.

Jane Wall discusses investment in Alchemab Therapeutics, Life Sciences Sector Plan: one year on, regulatory and trade links, Women in Biotech and BIA members lounge

Poolbeg Pharma today announces that the first patient has been dosed in the POLB 001 TOPICAL clinical trial.

How we boost entry-level diversity up to the senior level

Major VectorBee update reflects VectorBuilder’s continued investment in free, researcher-first tools for genetic engineering and vector design.

Applications are now open for BIA's 2027 Charity Partnership